ASKA Pharmaceutical Holdings Co., Ltd. (4514) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Towa Pharmaceutical Co., Ltd.

KYORIN Pharmaceutical Co., Ltd.

Zeria Pharmaceutical Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd.

Torii Pharmaceutical Co., Ltd.

Earth Corp.

Katakura Industries Co., Ltd.

Mochida Pharmaceutical Co., Ltd.

JCR Pharmaceuticals Co., Ltd.

Nxera Pharma Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Why is ASKA Pharmaceutical Holdings Co., Ltd. ?

Flat results in Dec 25

INTEREST(HY) At JPY 111 MM has Grown at 362.5%
ROCE(HY) Lowest at 7.33%
DEBT-EQUITY RATIO (HY) Highest at 10.38 %

Underperformed the market in the last 1 year

The stock has generated a return of 1.15% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 41.20%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ASKA Pharmaceutical Holdings Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

ASKA Pharmaceutical Holdings Co., Ltd.

1.15%

0.08

32.95%

Japan Nikkei 225

41.2%

1.45

28.34%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.07%

EBIT Growth (5y)

28.74%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

0.17

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.87

Tax Ratio

17.62%

Dividend Payout Ratio

30.56%

Pledged Shares

Institutional Holding

ROCE (avg)

9.64%

ROE (avg)

11.79%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.08

EV to EBIT

13.13

EV to EBITDA

9.24

EV to Capital Employed

1.08

EV to Sales

1.09

PEG Ratio

Dividend Yield

0.02%

ROCE (Latest)

8.20%

ROE (Latest)

8.27%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0.29% (YoY

NET SALES(Q)

Highest at JPY 19,233 MM

OPERATING PROFIT(Q)

Highest at JPY 3,031 MM

OPERATING PROFIT MARGIN(Q)

Highest at 15.76 %

PRE-TAX PROFIT(Q)

Highest at JPY 2,194 MM

NET PROFIT(Q)

Highest at JPY 1,678 MM

EPS(Q)

Highest at JPY 59.09

-15What is not working for the Company

INTEREST(HY)

At JPY 111 MM has Grown at 362.5%

ROCE(HY)

Lowest at 7.33%

DEBT-EQUITY RATIO (HY)

Highest at 10.38 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.37 times

CASH AND EQV(HY)

Lowest at JPY 14,032 MM

Here's what is working for ASKA Pharmaceutical Holdings Co., Ltd.

Net Sales

Highest at JPY 19,233 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Operating Profit

Highest at JPY 3,031 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JPY MM)

Operating Profit Margin

Highest at 15.76 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at JPY 2,194 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

Highest at JPY 1,678 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

EPS

Highest at JPY 59.09

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (JPY)

Raw Material Cost

Fallen by 0.29% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for ASKA Pharmaceutical Holdings Co., Ltd.

Interest

At JPY 111 MM has Grown at 362.5%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Debt-Equity Ratio

Highest at 10.38 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.37 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Cash and Eqv

Lowest at JPY 14,032 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents